Literature DB >> 25313209

Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.

A Espinel-Ingroff1, A Chowdhary2, G M Gonzalez3, J Guinea4, F Hagen5, J F Meis6, G R Thompson7, J Turnidge8.   

Abstract

Epidemiological cutoff values (ECVs) of isavuconazole are not available for Cryptococcus spp. The isavuconazole ECVs based on wild-type (WT) MIC distributions for 438 Cryptococcus neoformans nongenotyped isolates, 870 isolates of genotype VNI, and 406 Cryptococcus gattii isolates from six laboratories and different geographical areas were 0.06, 0.12, and 0.25 μg/ml, respectively. These ECVs may aid in detecting non-WT isolates with reduced susceptibilities to isavuconazole.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25313209      PMCID： PMC4291414          DOI： 10.1128/AAC.04055-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 2.  A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Authors:  A Dalhoff; P G Ambrose; J W Mouton
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

3.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

4.  In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-06-05       Impact factor: 5.948

5.  In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.

Authors:  Ferry Hagen; Maria-Teresa Illnait-Zaragozi; Karen H Bartlett; Daniëlle Swinne; Erik Geertsen; Corné H W Klaassen; Teun Boekhout; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

6.  Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Nathan P Wiederhold; Annette W Fothergill; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

7.  Amphotericin B: time for a new "gold standard".

Authors:  Luis Ostrosky-Zeichner; Kieren A Marr; John H Rex; Stuart H Cohen
Journal:  Clin Infect Dis       Date:  2003-07-22       Impact factor: 9.079

8.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

9.  Autochthonous and dormant Cryptococcus gattii infections in Europe.

Authors:  Ferry Hagen; M Francisca Colom; Daniëlle Swinne; Kathrin Tintelnot; Roberta Iatta; Maria Teresa Montagna; Josep M Torres-Rodriguez; Massimo Cogliati; Aristea Velegraki; Arjan Burggraaf; Alwin Kamermans; Johanna M Sweere; Jacques F Meis; Corné H W Klaassen; Teun Boekhout
Journal:  Emerg Infect Dis       Date:  2012-10       Impact factor: 6.883

10.  A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients.

Authors:  Edmond J Byrnes; Wenjun Li; Ping Ren; Yonathan Lewit; Kerstin Voelz; James A Fraser; Fred S Dietrich; Robin C May; Sudha Chaturvedi; Sudha Chatuverdi; Vishnu Chaturvedi; Vishnu Chatuverdi; Joseph Heitman
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823
View more
  23 in total

Review 1.  Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard.

Authors:  Shawn R Lockhart; Mahmoud A Ghannoum; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2017-02-15       Impact factor: 5.948

2.  In vitro activity of isavuconazole against clinically isolated yeasts from Chile.

Authors:  Eduardo Álvarez Duarte; Valentina Salas
Journal:  Braz J Microbiol       Date:  2020-07-07       Impact factor: 2.476

3.  Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Authors:  Nathan P Wiederhold; Laura Kovanda; Laura K Najvar; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.

Authors:  P F Herkert; F Hagen; G L de Oliveira Salvador; R R Gomes; M S Ferreira; V A Vicente; M D Muro; R L Pinheiro; J F Meis; F Queiroz-Telles
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-01       Impact factor: 3.267

5.  Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.

Authors:  Kathleen A Linder; Tejal N Gandhi; Marisa H Miceli
Journal:  Mycopathologia       Date:  2019-08-26       Impact factor: 2.574

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

Authors:  Matthew W McCarthy; Brad Moriyama; Ruta Petraitiene; Thomas J Walsh; Vidmantas Petraitis
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

8.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07

9.  Successful Isavuconazole Salvage Therapy for a Cryptococcus deuterogattii (AFLP6/VGII) Disseminated Infection in a European Immunocompetent Patient.

Authors:  Maria Soledad Cuetara; Juan José Jusdado Ruiz-Capillas; Maria Pilar Nuñez-Valentin; Elena Rodríguez Garcia; Elena Garcia-Benayas; Ricardo Rojo-Amigo; Jose Carlos Rodriguez-Gallego; Ferry Hagen; María Francisca Colom
Journal:  Mycopathologia       Date:  2021-06-11       Impact factor: 2.574

10.  An analysis of the population of Cryptococcus neoformans strains isolated from animals in Poland, in the years 2015-2019.

Authors:  Magdalena Florek; Urszula Nawrot; Agnieszka Korzeniowska-Kowal; Katarzyna Włodarczyk; Anna Wzorek; Anna Woźniak-Biel; Magdalena Brzozowska; Józef Galli; Anna Bogucka; Jarosław Król
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.